Featured Article
The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview
To examine the link between cardiovascular disease and sleep apnea, The Cardiology Advisor spoke with cardiologist Seth S. Martin, MD, MHS, FACC, FAHA and sleep specialist Rachel Marie E. Salas, MD, FAAN.
Latest Features
The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview
To examine the link between cardiovascular disease and sleep apnea, The Cardiology Advisor spoke with cardiologist Seth S. Martin, MD, MHS, FACC, FAHA and sleep specialist Rachel Marie E. Salas, MD, FAAN.
Managing Heart Failure: Improving Quality of Life and Preventing Excerbations
Heart failure is the number 1 reason for patient re-admittance to acute-care facilities according to the American Heart Association.
Preventing Heart Failure One Risk Factor at a Time
Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.
Hope for Heart Failure in Thyroid Hormone Therapy
Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.
Premature Ventricle Contractions in Heart Failure: A Closer Examination
A primer on premature ventricle contractions with commentary from 2 arrhythmic/heart failure experts.
ARVD/Cardiomyopathy: Interview with Expert Hugh Calkins, MD
While ARVD/C management has greatly improved, more precautions—particularly in genetic testing and exercise—need to be taken.
Clinician Viewpoints on the "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure"
Drs Tauras and Patel from Montefiore Medical Center in the Bronx, New York weigh in on what the new heart failure therapeutic guidelines mean for practicing clinicians.
Managing Cardiovascular Complications of Oncology Treatment
Clinicians seek stronger collaboration between cardiology and oncology as well as evidence-based treatment guidelines.
Ixmyelocel-T Cell-Based Therapy Reduced Cardiac Events in Heart Failure
Ixmyelocel-T therapy reduced clinical cardiac events and improved patient outcomes.
Better Late Than Never: Exercise as Primary and Secondary Prevention in CVD
Exercise's potential positive effects on cardiovascular disease and heart failure may be possible regardless of frequency and time of initiation.
Latest News
Sacubitril/Valsartan vs Enalapril for Physical Activity Improvement in HFrEF
Sacubitril/valsartan was associated with greater improvements in physical and social activities in patients with heart failure with reduced ejection fraction than enalapril.
Sacubitril/Valsartan May Help Preserve Kidney Function in Patients With HFrEF
Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline (-1.3 vs -1.8mL/min/1.73m2 per year; P<0.0001).
ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation
New Class 1 recommendations involve the referral of inpatients and outpatients to cardiac rehabilitation programs that include exercise training.
Elamipretide Granted Orphan Drug Status for Barth Syndrome
The TAZPOWER study is a randomized, double-blind, placebo-controlled Phase 2/3 crossover study evaluating the safety and efficacy of elamipretide (daily subcutaneous injections) in 12 male patients (aged ≥12 years) with genetically-confirmed Barth syndrome.
Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
Entresto may improve limitations in physical and social activities in patients with heart failure.
Oral Tx for Transthyretin Cardiomyopathy Meets Primary Endpoint in Study
Although they acknowledge the preliminary data is subject to further analysis, they say it demonstrates a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months.
Cardiovascular Outcomes of SGLT-2i vs Other Glucose-Lowering Drugs in T2D
A recent study evaluated the effects of SGLT-2i and other glucose-lowering drugs on cardiovascular event outcomes in patients with type 2 diabetes from 6 countries in 3 world regions.
Automated Detection of Atrial Fibrillation Through Smartwatch Technology
A Smartwatch band paired with an app records a 30-second single-lead rhythm strip.
Outcomes With Aspirin for Primary Prevention in Heart Failure, Type 2 Diabetes
Primary prevention with aspirin may reduce all-cause mortality in patients with heart failure and type 2 diabetes.
LVAD Shared Decision-Making Program Demonstrates Improved Patient Knowledge
A shared decision-making program between patients with end-stage heart failure being considered for destination therapy left ventricular assist device and their caregivers was associated with improvement in patient knowledge.
The Cardiology Advisor Articles
- The Mounting Evidence Against Electronic Cigarette Use
- Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
- Oxygen Therapy in Acute MI Not Associated With Clinical Benefit
- Nonpsychotic Cannabinoids in Hypertension: Benefits and Harms
- ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation